List of Excipients in Branded Drug VORICONAZOLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
XGen Pharmaceuticals DJB Inc	VORICONAZOLE	voriconazole	39822-1077	HYDROXYPROPYLBETADEX
Greenstone LLC	VORICONAZOLE	voriconazole	59762-0930	CROSCARMELLOSE SODIUM
Greenstone LLC	VORICONAZOLE	voriconazole	59762-0930	HYPROMELLOSE
Greenstone LLC	VORICONAZOLE	voriconazole	59762-0930	LACTOSE MONOHYDRATE
Greenstone LLC	VORICONAZOLE	voriconazole	59762-0930	MAGNESIUM STEARATE
Greenstone LLC	VORICONAZOLE	voriconazole	59762-0930	POVIDONE

Generic Drugs Containing VORICONAZOLE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	voriconazole	0378-1626	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	voriconazole	0378-1626	HYPROMELLOSE 2910
Mylan Pharmaceuticals Inc	voriconazole	0378-1626	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	voriconazole	0378-1626	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	voriconazole	0378-1626	POVIDONE
Mylan Pharmaceuticals Inc	voriconazole	0378-1626	STARCH, CORN

What are the Most Frequently-Used Excipients in VORICONAZOLE?

# Of NDCs	Excipient
7	ANHYDROUS CITRIC ACID
9	BETADEX SULFOBUTYL ETHER SODIUM
26	CROSCARMELLOSE SODIUM
9	HYPROMELLOSE
15	HYPROMELLOSE 2910
26	LACTOSE MONOHYDRATE

Excipient Strategy and Commercial Opportunities for Voriconazole

Last updated: February 28, 2026

What is the Role of Excipients in Voriconazole Formulations?

Excipients are inactive substances used alongside the active pharmaceutical ingredient (API) to enhance drug stability, bioavailability, manufacturability, and patient compliance. For voriconazole, an antifungal agent, the excipient selection impacts its solubility, stability, and delivery profile.

Key excipients in voriconazole formulations include:

• Polyethylene Glycol (PEG): Used as a solvent and stabilizer in injectable formulations.
• Sodium Chloride: Utilized for isotonicity in IV solutions.
• Hydroxypropyl Beta-Cyclodextrin (HP-β-CD): Enhances solubility for IV and oral formulations.
• Sodium Lauryl Sulfate: Acts as a surfactant in some formulations.
• Excipients in Oral Formulations: Include microcrystalline cellulose, croscarmellose sodium, and magnesium stearate for tablets.

Excipients are selected based on the route of administration, stability requirements, and patient tolerability.

How Does Excipient Strategy Impact Formulation Innovation?

Formulation innovation centers on improving bioavailability, reducing side effects, and extending shelf life. The strategic inclusion of solubilizers like HP-β-CD enhances oral bioavailability, especially crucial given voriconazole’s poor water solubility.

In IV formulations, minimizing hypersensitivity reactions involves stabilizing excipients to prevent degradation. Novel excipients or combinations can also facilitate controlled-release delivery, reducing dosing frequency.

Developing alternative excipients can address challenges such as:

• Reducing excipient-related adverse reactions (e.g., infusion site reactions).
• Enhancing chemical stability under various environmental conditions.
• Improving patient compliance via taste-masking or reduced pill burden.

What Are the Commercial Opportunities in Excipient-Enhanced Voriconazole Products?

The choice and innovation of excipients open multiple revenue streams and product differentiation:

1. Enhanced Oral Formulations

• Use of cyclodextrins and surfactants to increase solubility.
• Development of sustained-release tablets with excipients like ethylcellulose.
• Partnership opportunities with excipient manufacturers for proprietary complexes.

2. Injectable Formulations

• Optimization of PEG-based and cyclodextrin stabilizers to improve shelf-life and reduce infusion reactions.
• Use of innovative excipients (e.g., polysorbates) for stability and tolerability.

3. Combination and Fixed-Dose Products

• Combining voriconazole with excipients that improve absorption or reduce variability.
• Fixed-dose combinations with other antifungals or supportive agents.

4. Regulatory and Manufacturing Differentiation

• Excipient patents can create barriers to entry and extend market dominance.
• Developing excipient formulations that meet stringent bioequivalence and stability standards across markets.

5. Market Expansion

• Pediatric and geriatric formulations with excipients tailored for specific tolerability needs.
• Targeting unmet needs in immunocompromised populations with novel delivery options.

How Do Regulatory Frameworks Influence Excipient Development?

Regulatory agencies like the FDA and EMA set strict guidelines on excipient safety, especially for intravenous and pediatric products. Innovations must satisfy safety, biological compatibility, and stability criteria, often requiring extensive testing.

Development timelines for excipient innovations include:

• Toxicological evaluation.
• Stability testing under ICH guidelines.
• Bioequivalence and tolerability studies.

Patents related to new excipients or novel formulations can provide 10–15 years of market exclusivity.

What Are the Emerging Trends and Challenges?

Emerging trends include:

• Use of biodegradable, plant-derived excipients to address safety concerns.
• Incorporation of nanotechnology for targeted delivery.
• Development of excipient systems that enable oral, IV, and topical formulations.

Challenges involve:

• Ensuring excipient supply chain consistency amid global disruptions.
• Meeting evolving safety profile standards.
• Balancing formulation complexity with manufacturing costs.

Key Takeaways

• Excipient selection directly influences voriconazole’s bioavailability, stability, and patient tolerability.
• Innovation in excipients creates opportunities in oral, injectable, and combination products.
• Patents on novel excipient systems can extend market exclusivity.
• Regulatory standards shape excipient development timelines and safety evaluations.
• Market potential exists in pediatric, geriatric, and targeted delivery formulations.

FAQs

1. Which excipient has the most significant impact on voriconazole's bioavailability?
Hydroxypropyl Beta-Cyclodextrin (HP-β-CD) enhances solubility, directly improving bioavailability for oral and IV formulations.

2. Are there safety concerns associated with excipients in voriconazole formulations?
Yes. Surfactants and stabilizers like polysorbates require safety evaluation due to potential hypersensitivity and toxicity risks, especially in IV formulations.

3. How do patented excipient systems provide competitive advantages?
Patents protect proprietary excipient complexes or delivery systems, preventing generic competition and enabling premium pricing.

4. What regulatory considerations affect excipient innovation in voriconazole products?
Regulations demand thorough safety, stability, and bioequivalence testing. Pediatric and IV formulations face stricter scrutiny.

5. What market segments are most attractive for excipient-driven innovation?
Pediatric and immunocompromised patient populations are primary targets, with opportunities in long-acting, reduced-dose, or combination formulations.

---

References

[1] U.S. Food and Drug Administration. (2021). Guidance for Industry: Excipients. https://www.fda.gov
[2] European Medicines Agency. (2020). Guideline on the excipients in medicinal products. https://www.ema.europa.eu
[3] Evans, G. A. (2019). Advances in formulation strategies for poor water-soluble drugs. International Journal of Pharmaceutics, 567, 118526.